| HOME >> MEDICINE >> TECHNOLOGY |
10.2.2 Managing Risk Factors and Opportunity for Growth of Drugs Used for Secondary Prevention
10.2.3 Novel Therapeutics Poised to Meet Needs in the Patient Population
10.2.4 Switching to OTC
10.2.5 The Threat of Generic Products
10.2.6 Termination of Late-Stage Clinical Trials
10.2.7 Downward Cost Pressures
10.2.8 A Buyer's Market?
10.2.9 Challenges to the Statin Drug Industry and Market
11. Opinion from Our Survey
11.1 Interview with Dr Mauricio Cohen, Associate Professor of Medicine, University of Miami Miller School of Medicine; Director, Cardiac Catheterization Laboratory, University of Miami Hospital, US
11.1.1 Regado Biosciences' Lead Pipeline Anticoagulant Drug Candidate: REG1
11.1.2 Advantages Offered by the REG1 Anticoagulation System
11.1.3 Unmet Needs and Future of ACS Treatment Development
12. Conclusions
12.1 Principal Market Drivers
12.2 Principal Market Restraints
12.3 Driving Factors for the Success of Pipeline Drugs
12.4 Concluding Remarks on the Future of the Market
List of Tables
Table 2.1 Hospital Admissions in the US Due to ACS, by Type of Condition, 2007
Table 4.1 List of ACS Drugs Recommended by ACC/AHA and ESC
Table 4.2 World ACS Treatment Market by Leading Therapeutic Classes ($m), 2010
Table 4.3 Leading Drugs in the World ACS Treatment Market ($m), 2010
Table 4.4 Plavix: Total Sales and Sales from ACS ($m), 2009 & 2010
Table 4.5 World ACS Treatment Market Forecast ($m), 2010-2021
Table 4.6 Market Shares (%) of Leading Therapeutic Classes in the ACS Treatment Market, 2010, 2015 & 2021
Table 5.1 Platelet Aggregation Inhibitors Market by Leading Products ($m), 2010
Table 5.2 Platelet Aggregation Inhibitors Market Sales Forecast ($m), 2010-2021
Table 5.3 List of Clopidog
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |